Literature DB >> 22067418

Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.

Eui Hyun Kim1, Min Chul Oh, Eun Jig Lee, Sun Ho Kim.   

Abstract

BACKGROUND: The suppression of the growth hormone (GH) on an oral glucose tolerance test (OGTT) has been accepted as the most reliable parameter for determining remission of acromegaly.
OBJECTIVE: To evaluate the role of immediate postoperative GH level and 1-week postoperative OGTT as early predictive tools of long-term surgical remission.
METHODS: One hundred ninety-four acromegalic patients who received transsphenoidal tumor resection and were followed up for > 1.5 years (3.80 ± 0.17 years) with at least 3 postoperative OGTTs were evaluated. Level of GH was measured 2, 6, 12, 18, 24, 48, and 72 hours postoperatively, and an OGTT was performed 1 week after surgery, every 6 months for the first 3 years, and annually thereafter.
RESULTS: One hundred seventy-seven patients underwent gross total resection; long-term remission was achieved in 153. The GH level at 24 hours after surgery showed the highest predictive power for long-term remission. Long-term remission was maintained in 125/127 (98.4%) patients who had nadir GH levels < 1.0 μg/L on an early postoperative OGTT. However, when nadir GH levels were > 1.0 μg/L on an early postoperative OGTT, long-term remission was observed in 28 patients (28 of 67, 41.8%) in a delayed fashion. One-week postoperative OGTT had a sensitivity of 81.7% and specificity of 95.1% for predicting remission.
CONCLUSION: Immediate postoperative GH level is a very good predictor of long-term outcome in acromegaly. One-week postoperative OGTT is also a good predictor with high specificity. These findings may provide critical information for the determination of adjuvant treatment after surgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22067418     DOI: 10.1227/NEU.0b013e31823f5c16

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  16 in total

1.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

2.  Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.

Authors:  Liang Lv; Yong Jiang; Senlin Yin; Yu Hu; Cheng Chen; Weichao Ma; Shu Jiang; Peizhi Zhou
Journal:  Endocrine       Date:  2019-07-31       Impact factor: 3.633

Review 3.  Current best practice in the management of patients after pituitary surgery.

Authors:  Alessandro Prete; Salvatore Maria Corsello; Roberto Salvatori
Journal:  Ther Adv Endocrinol Metab       Date:  2017-03-01       Impact factor: 3.565

Review 4.  Management options for persistent postoperative acromegaly.

Authors:  Nestoras Mathioudakis; Roberto Salvatori
Journal:  Neurosurg Clin N Am       Date:  2012-08-09       Impact factor: 2.509

5.  Drug-naive patients with schizophrenia have metabolic disorders that are not associated with polymorphisms in the LEP (-2548G/A) and 5-HTR2C (-759C/T) genes.

Authors:  Jinhong Chen; Liwen Tan; Zhou Long; Lifeng Wang; Li Hu; Dong Yang
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

6.  Early postoperative prediction of both disease remission and long-term disease control in acromegaly using the oral glucose tolerance test.

Authors:  Kiyohiko Sakata; Yui Nagata; Nobuyuki Takeshige; Jin Kikuchi; Masato Shikata; Kenji Ashida; Masatoshi Nomura; Motohiro Morioka
Journal:  Hormones (Athens)       Date:  2021-03-18       Impact factor: 2.885

7.  Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly.

Authors:  Pamela U Freda; Jeffrey N Bruce; Carlos Reyes-Vidal; Simran Singh; Yessica DeLeon; Zhezhen Jin; Alexander G Khandji; Serge Cremers; Kalmon D Post
Journal:  Pituitary       Date:  2020-10-30       Impact factor: 4.107

Review 8.  Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?

Authors:  Cheol Ryong Ku; Vladimir Melnikov; Zhaoyun Zhang; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

9.  Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas.

Authors:  Nicholas A Tritos; Pouneh K Fazeli; Ann McCormack; Susana M Mallea-Gil; Maria M Pineyro; Mirjam Christ-Crain; Stefano Frara; Artak Labadzhyan; Adriana G Ioachimescu; Ilan Shimon; Yutaka Takahashi; Mark Gurnell; Maria Fleseriu
Journal:  Pituitary       Date:  2021-07-20       Impact factor: 4.107

10.  No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study).

Authors:  Cheol Ryong Ku; Eun Yeong Choe; Jae Won Hong; Eui Hyun Kim; Se Hee Park; Sun Ho Kim; Eun Jig Lee
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.